Sulfasalazine Attenuates Staphylococcal Enterotoxin B-induced Immune Responses

Overview

Journal Toxins (Basel)

Publisher MDPI

Specialty Toxicology

Date 2015 Feb 18

PMID 25688664

Citations 3

Authors

Teresa Krakauer

Affiliations

Soon will be listed here.

Abstract

Staphylococcal enterotoxin B (SEB) and related exotoxins are important virulence factors produced by Staphylococcus aureus as they cause human diseases such as food poisoning and toxic shock. These toxins bind directly to cells of the immune system resulting in hyperactivation of both T lymphocytes and monocytes/macrophages. The excessive release of proinflammatory cytokines from these cells mediates the toxic effects of SEB. This study examined the inhibitory activities of an anti-inflammatory drug, sulfasalazine, on SEB-stimulated human peripheral blood mononuclear cells (PBMC). Sulfasalazine dose-dependently inhibited tumor necrosis factor α, interleukin 1 (IL-1) β, IL-2, IL-6, interferon γ (IFNγ), and various chemotactic cytokines from SEB-stimulated human PBMC. Sulfasalazine also potently blocked SEB-induced T cell proliferation and NFκB activation. These results suggest that sulfasalazine might be useful in mitigating the toxic effects of SEB by blocking SEB-induced host inflammatory cascade and signaling pathways.

Citing Articles

The SEB1741 Aptamer Is an Efficient Tool for Blocking CD4+ T Cell Activation Induced by Staphylococcal Enterotoxin B.

Chavez-Galan L, Ruiz A, Ramon-Luing L, Escamilla-Gutierrez A, Sanchez-Moncivais A, Tecuatzi-Cadena B Molecules. 2023; 28(8).

PMID: 37110712 PMC: 10142257. DOI: 10.3390/molecules28083480.

Enterotoxins: Microbial Proteins and Host Cell Dysregulation.

Krakauer T Toxins (Basel). 2016; 8(1).

PMID: 27096148 PMC: 4728539. DOI: 10.3390/toxins8010017.

Targeting Staphylococcus aureus Toxins: A Potential form of Anti-Virulence Therapy.

Kong C, Neoh H, Nathan S Toxins (Basel). 2016; 8(3).

PMID: 26999200 PMC: 4810217. DOI: 10.3390/toxins8030072.

References

Krakauer T . Suppression of endotoxin- and staphylococcal exotoxin-induced cytokines and chemokines by a phospholipase C inhibitor in human peripheral blood mononuclear cells. Clin Diagn Lab Immunol. 2001; 8(2):449-53. PMC: 96079. DOI: 10.1128/CDLI.8.2.449-453.2001. View

Krakauer T . Update on staphylococcal superantigen-induced signaling pathways and therapeutic interventions. Toxins (Basel). 2013; 5(9):1629-54. PMC: 3798877. DOI: 10.3390/toxins5091629. View

Darenberg J, Soderquist B, Henriques Normark B, Norrby-Teglund A . Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome. Clin Infect Dis. 2004; 38(6):836-42. DOI: 10.1086/381979. View

Hoult J . Pharmacological and biochemical actions of sulphasalazine. Drugs. 1986; 32 Suppl 1:18-26. DOI: 10.2165/00003495-198600321-00005. View

Jupin C, Anderson S, Damais C, ALOUF J, Parant M . Toxic shock syndrome toxin 1 as an inducer of human tumor necrosis factors and gamma interferon. J Exp Med. 1988; 167(3):752-61. PMC: 2188868. DOI: 10.1084/jem.167.3.752. View

Carlsson R, Fischer H, Sjogren H . Binding of staphylococcal enterotoxin A to accessory cells is a requirement for its ability to activate human T cells. J Immunol. 1988; 140(8):2484-8. View

Choi Y, Kotzin B, Herron L, Callahan J, Marrack P, Kappler J . Interaction of Staphylococcus aureus toxin "superantigens" with human T cells. Proc Natl Acad Sci U S A. 1989; 86(22):8941-5. PMC: 298406. DOI: 10.1073/pnas.86.22.8941. View

Trede N, Castigli E, Geha R, Chatila T . Microbial superantigens induce NF-kappa B in the human monocytic cell line THP-1. J Immunol. 1993; 150(12):5604-13. View

Kotzin B, Leung D, Kappler J, Marrack P . Superantigens and their potential role in human disease. Adv Immunol. 1993; 54:99-166. DOI: 10.1016/s0065-2776(08)60534-9. View

10.

Miethke T, Wahl C, Regele D, GAUS H, Heeg K, Wagner H . Superantigen mediated shock: a cytokine release syndrome. Immunobiology. 1993; 189(3-4):270-84. DOI: 10.1016/S0171-2985(11)80362-1. View

11.

Rains C, Noble S, Faulds D . Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs. 1995; 50(1):137-56. DOI: 10.2165/00003495-199550010-00009. View

12.

Gadangi P, Longaker M, Naime D, Levin R, Recht P, Montesinos M . The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol. 1996; 156(5):1937-41. View

13.

Neumann B, Engelhardt B, Wagner H, Holzmann B . Induction of acute inflammatory lung injury by staphylococcal enterotoxin B. J Immunol. 1997; 158(4):1862-71. View

14.

Barnes P, Karin M . Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997; 336(15):1066-71. DOI: 10.1056/NEJM199704103361506. View

15.

Lappas M, Yee K, Permezel M, Rice G . Sulfasalazine and BAY 11-7082 interfere with the nuclear factor-kappa B and I kappa B kinase pathway to regulate the release of proinflammatory cytokines from human adipose tissue and skeletal muscle in vitro. Endocrinology. 2004; 146(3):1491-7. DOI: 10.1210/en.2004-0809. View

16.

Fraser J, Proft T . The bacterial superantigen and superantigen-like proteins. Immunol Rev. 2008; 225:226-43. DOI: 10.1111/j.1600-065X.2008.00681.x. View

17.

Krakauer T . Nuclear factor-kappaB: fine-tuning a central integrator of diverse biologic stimuli. Int Rev Immunol. 2008; 27(5):286-92. DOI: 10.1080/08830180802317957. View

18.

Vallabhapurapu S, Karin M . Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol. 2009; 27:693-733. DOI: 10.1146/annurev.immunol.021908.132641. View

19.

Lappin E, Ferguson A . Gram-positive toxic shock syndromes. Lancet Infect Dis. 2009; 9(5):281-90. DOI: 10.1016/S1473-3099(09)70066-0. View

20.

Langley R, Patel D, Jackson N, Clow F, Fraser J . Staphylococcal superantigen super-domains in immune evasion. Crit Rev Immunol. 2010; 30(2):149-65. DOI: 10.1615/critrevimmunol.v30.i2.40. View